|
AR058135A1
(es)
|
2005-10-21 |
2008-01-23 |
Chugai Pharmaceutical Co Ltd |
Agentes para el tratamiento de cardiopatias
|
|
CN101495146B
(zh)
|
2006-04-07 |
2012-10-17 |
国立大学法人大阪大学 |
肌肉再生促进剂
|
|
PL2041177T3
(pl)
|
2006-06-02 |
2012-09-28 |
Regeneron Pharma |
Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
US8629244B2
(en)
|
2006-08-18 |
2014-01-14 |
Ablynx N.V. |
Interleukin-6 receptor binding polypeptides
|
|
JP2010512734A
(ja)
*
|
2006-12-13 |
2010-04-30 |
アブリンクス エン．ヴェー． |
Ｉｌ−６／ｉｌ−６受容体複合体等受容体介在性シグナル伝達に関与する複合体に特異的なポリペプチド
|
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
|
ES2564392T3
(es)
|
2007-01-23 |
2016-03-22 |
Shinshu University |
Inhibidores de IL-6 para el tratamiento de rechazo crónico
|
|
CN105017427A
(zh)
|
2007-06-25 |
2015-11-04 |
艾斯巴技术-诺华有限责任公司 |
修饰抗体的方法和具有改善的功能性质的修饰抗体
|
|
WO2009010539A2
(en)
*
|
2007-07-19 |
2009-01-22 |
Ablynx. N.V. |
Receptor for interleukin-6 (il-6) from macaca fascicularis
|
|
WO2009095489A2
(en)
*
|
2008-02-01 |
2009-08-06 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
|
|
WO2009109635A2
(en)
*
|
2008-03-05 |
2009-09-11 |
Ablynx Nv |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
|
AU2009237662A1
(en)
|
2008-04-17 |
2009-10-22 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
|
HUE042053T2
(hu)
|
2008-06-05 |
2019-06-28 |
Ablynx Nv |
Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
|
|
WO2009148148A1
(ja)
|
2008-06-05 |
2009-12-10 |
国立がんセンター総長が代表する日本国 |
神経浸潤抑制剤
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
US9034325B2
(en)
|
2008-07-22 |
2015-05-19 |
Ablynx N.V. |
Amino acid sequences directed against multitarget scavenger receptors and polypeptides
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
US9327022B2
(en)
|
2008-10-14 |
2016-05-03 |
National Research Council Of Canada |
BSA-specific antibodies
|
|
CA2746395C
(en)
*
|
2008-12-10 |
2019-07-09 |
Ablynx N.V. |
Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
|
|
US9260508B2
(en)
|
2008-12-19 |
2016-02-16 |
Ablynx N.V. |
Method for generation of immunoglobulin sequences
|
|
US20110311515A1
(en)
|
2009-01-14 |
2011-12-22 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
KR20110110349A
(ko)
*
|
2009-01-29 |
2011-10-06 |
아보트 러보러터리즈 |
Ｉｌ-1 결합 단백질
|
|
EP2403873A1
(en)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
WO2010107108A1
(ja)
*
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
関節リウマチ治療剤
|
|
KR20130119990A
(ko)
*
|
2009-04-10 |
2013-11-01 |
아블린쓰 엔.브이. |
Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
|
|
US10618964B2
(en)
|
2009-04-10 |
2020-04-14 |
Ablynx N.V. |
Nanobody against IL-6R
|
|
CA2759370C
(en)
|
2009-04-30 |
2020-02-11 |
Peter Schotte |
Method for the production of domain antibodies
|
|
DK2438087T3
(en)
|
2009-06-05 |
2017-08-28 |
Ablynx Nv |
TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
|
|
US9150640B2
(en)
|
2009-07-10 |
2015-10-06 |
Ablynx N.V. |
Method for the production of variable domains
|
|
PT2473527T
(pt)
|
2009-09-03 |
2017-02-27 |
Ablynx NV |
Formulações estáveis de polipéptidos e seus usos
|
|
US20120283415A1
(en)
|
2009-09-10 |
2012-11-08 |
Ucb Pharma S.A. |
Multivalent Antibodies
|
|
UY32920A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moleculas de unión biespecíficas para la terapia anti-angiogénesis
|
|
US20110195494A1
(en)
|
2009-10-02 |
2011-08-11 |
Boehringer Ingelheim International Gmbh |
Dll4-binging molecules
|
|
US20110117113A1
(en)
|
2009-10-09 |
2011-05-19 |
Gerald Beste |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
EP2507262A1
(en)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
EP2506874A1
(en)
|
2009-12-01 |
2012-10-10 |
Ablynx N.V. |
Von willebrand factor specific binding agents and uses thereof
|
|
WO2011073180A1
(en)
|
2009-12-14 |
2011-06-23 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
CA2788993A1
(en)
|
2010-02-05 |
2011-08-11 |
Ablynx N.V. |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
ES2931330T3
(es)
|
2010-02-11 |
2022-12-28 |
Ablynx Nv |
Métodos y composiciones para la preparación de aerosoles
|
|
WO2011098518A2
(en)
|
2010-02-11 |
2011-08-18 |
Ablynx Nv |
Delivery of immunoglobulin variable domains and constructs thereof
|
|
CA2788275A1
(en)
|
2010-03-03 |
2011-09-09 |
Boehringer Ingelheim International Gmbh |
Biparatopic abeta binding polypeptides
|
|
EP2552962B1
(en)
|
2010-03-26 |
2016-03-23 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
KR20130080790A
(ko)
|
2010-05-20 |
2013-07-15 |
아블린쓰 엔.브이. |
Ｈｅｒ３와 관련된 생물학적 물질들
|
|
JP6051049B2
(ja)
|
2010-05-28 |
2016-12-21 |
中外製薬株式会社 |
抗腫瘍ｔ細胞応答増強剤
|
|
EP2582811B1
(en)
*
|
2010-06-17 |
2019-09-18 |
VIB vzw |
Increased protein expression through increased membrane formation
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
|
US11644471B2
(en)
|
2010-09-30 |
2023-05-09 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
EA037063B1
(ru)
|
2010-11-08 |
2021-02-01 |
Аблинкс Н.В. |
Cxcr2-связывающие полипептиды
|
|
AU2012234284B2
(en)
|
2011-03-28 |
2015-10-08 |
Ablynx Nv |
Bispecific anti-CXCR7 immunoglobulin single variable domains
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
US20130078247A1
(en)
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
EP2707382B1
(en)
|
2011-05-09 |
2019-07-17 |
Ablynx NV |
Method for the production of immunoglobulin single variable domains
|
|
RU2661677C2
(ru)
|
2011-05-27 |
2018-07-18 |
Аблинкс Нв |
Ингибирование резорбции кости с помощью связывающих rank-l пептидов
|
|
CA2839834A1
(en)
|
2011-06-21 |
2012-12-27 |
Vib Vzw |
Binding domains directed against gpcr:g protein complexes and uses derived thereof
|
|
EP4218933A1
(en)
|
2011-06-23 |
2023-08-02 |
Ablynx NV |
Serum albumin binding proteins
|
|
EP4350345A3
(en)
|
2011-06-23 |
2024-07-24 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
IN2014CN00437A
(enExample)
|
2011-06-23 |
2015-04-03 |
Ablynx Nv |
|
|
FI2974737T3
(fi)
|
2011-06-23 |
2026-01-22 |
Ablynx Nv |
Tekniikoita tietyn proteiinihäiriön ennakoimiseksi, havaitsemiseksi ja vähentämiseksi immunoglobuliinin yhtä muuttuvaa domeenia käsittävissä määrityksissä
|
|
EP2944653A1
(en)
|
2011-06-23 |
2015-11-18 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
EA027160B1
(ru)
|
2011-08-17 |
2017-06-30 |
Глаксо Груп Лимитед |
Модифицированные белки и пептиды
|
|
DK2747782T3
(en)
|
2011-09-23 |
2018-04-23 |
Ablynx Nv |
Long-term inhibition of interleukin-6-mediated signal transmission
|
|
US9346884B2
(en)
|
2011-09-30 |
2016-05-24 |
Ablynx N.V. |
Biological materials related to c-Met
|
|
EP2747783B1
(en)
|
2011-09-30 |
2017-06-14 |
Ablynx N.V. |
Biological materials related to c-met
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
JP2015506373A
(ja)
|
2012-01-26 |
2015-03-02 |
アムジエン・インコーポレーテツド |
成長分化因子１５（ｇｄｆ−１５）ポリペプチド
|
|
PH12021553014A1
(en)
|
2012-02-27 |
2022-09-05 |
Ablynx Nv |
Cx3cr1-binding polypeptides
|
|
JP5970734B2
(ja)
|
2012-03-30 |
2016-08-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ａｎｇ２結合分子
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
ES2715279T3
(es)
|
2012-05-24 |
2019-06-03 |
Vib Vzw |
Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
CN112858672A
(zh)
|
2013-01-30 |
2021-05-28 |
弗拉芒区生物技术研究所 |
用于筛选和药物发现目的的新型嵌合多肽
|
|
EP3590578A1
(en)
|
2013-02-05 |
2020-01-08 |
VIB vzw |
Muscarinic acetylcholine receptor binding agents and uses thereof
|
|
AU2014229952B2
(en)
|
2013-03-15 |
2018-10-04 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
|
|
WO2014200018A1
(ja)
|
2013-06-11 |
2014-12-18 |
独立行政法人 国立精神・神経医療研究センター |
再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
|
|
UY35686A
(es)
|
2013-07-31 |
2015-01-30 |
Amgen Inc |
Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
|
|
ES2698976T3
(es)
|
2013-11-04 |
2019-02-06 |
Inst Nat Sante Rech Med |
Anticuerpo sintético de un solo dominio
|
|
EP2873680A1
(en)
*
|
2013-11-13 |
2015-05-20 |
F.Hoffmann-La Roche Ag |
Oligopeptide and methods for producing conjugates thereof
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US20160326220A1
(en)
|
2013-12-24 |
2016-11-10 |
Vib Vzw |
Secretion and functional display of chimeric polypeptides
|
|
US10233241B2
(en)
|
2014-01-30 |
2019-03-19 |
Vib Vzw |
Opioid receptor binding agents and uses thereof
|
|
KR20180091115A
(ko)
|
2014-05-16 |
2018-08-14 |
아블린쓰 엔.브이. |
개선된 면역글로불린 가변 도메인
|
|
HUE056738T2
(hu)
|
2014-05-16 |
2022-03-28 |
Ablynx Nv |
Eljárás gyógyszer elleni antitestek, különösen kezelés kapcsán kialakuló gyógyszer elleni antitestek detektálására és/vagy mérésére
|
|
KR20250099289A
(ko)
|
2014-05-16 |
2025-07-01 |
아블린쓰 엔.브이. |
개선된 면역글로불린 가변 도메인
|
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
WO2016012363A1
(en)
|
2014-07-22 |
2016-01-28 |
Vib Vzw |
Methods to select for agents that stabilize protein complexes
|
|
CN106999517A
(zh)
|
2014-10-07 |
2017-08-01 |
免疫医疗公司 |
抗体‑药物缀合物的新辅助剂用途
|
|
EP3209327A1
(en)
|
2014-10-21 |
2017-08-30 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
US11426468B2
(en)
|
2014-12-19 |
2022-08-30 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
|
US11306139B2
(en)
*
|
2015-03-20 |
2022-04-19 |
Ablynx N.V. |
Glycosylated immunoglobulin single variable domains
|
|
WO2016156466A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Peptide construct having a protease-cleavable linker
|
|
CA2981103A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Polypeptides
|
|
US10273305B2
(en)
|
2015-04-02 |
2019-04-30 |
Ablynx N.V. |
Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
|
|
CN107428837A
(zh)
|
2015-04-22 |
2017-12-01 |
免疫医疗公司 |
循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
|
|
HUE045437T2
(hu)
|
2015-05-13 |
2019-12-30 |
Ablynx Nv |
TCR-alfa-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek
|
|
RS65904B1
(sr)
|
2015-05-13 |
2024-09-30 |
Ablynx Nv |
Polipeptidi koji regrutuju t ćelije na osnovu reaktivnosti cd3
|
|
WO2016186154A1
(ja)
|
2015-05-19 |
2016-11-24 |
国立研究開発法人国立精神・神経医療研究センター |
多発性硬化症（ｍｓ）患者の新規治療適用判断方法
|
|
WO2016187594A1
(en)
|
2015-05-21 |
2016-11-24 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
NO2768984T3
(enExample)
|
2015-11-12 |
2018-06-09 |
|
|
|
EP3974449A1
(en)
|
2015-11-13 |
2022-03-30 |
Ablynx NV |
Improved serum albumin-binding immunoglobulin variable domains
|
|
JO3740B1
(ar)
|
2015-11-18 |
2021-01-31 |
Merck Sharp & Dohme |
روابط pd1/ctla4
|
|
CA3004900C
(en)
|
2015-11-18 |
2021-08-10 |
Merck Sharp & Dohme Corp. |
Ctla4 binders
|
|
TW202216787A
(zh)
|
2015-11-18 |
2022-05-01 |
美商默沙東藥廠 |
Pd1及／或 lag3結合劑
|
|
CN114605530B
(zh)
|
2015-11-18 |
2025-06-10 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合剂
|
|
SG11201803976VA
(en)
|
2015-11-27 |
2018-06-28 |
Ablynx Nv |
Polypeptides inhibiting cd40l
|
|
TWI734719B
(zh)
|
2015-12-04 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
在腫瘤細胞中拮抗ｗｎｔ信號傳遞之雙抗體結合部位（ｂｉｐａｒａｔｏｐｉｃ）多肽
|
|
WO2017125578A1
(en)
|
2016-01-21 |
2017-07-27 |
Vhsquared Limited |
Polypeptides
|
|
EP3430055B1
(en)
|
2016-03-17 |
2020-10-28 |
Oslo Universitetssykehus HF |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
JP2019523213A
(ja)
|
2016-05-02 |
2019-08-22 |
アブリンクス エン．ヴェー． |
Ｒｓｖ感染の処置
|
|
CA3024683A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3471761A2
(en)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
|
MX2018016413A
(es)
|
2016-06-23 |
2019-05-09 |
Ablynx Nv |
Ensayos farmacocineticos mejorados para dominios variables unicos de inmunoglobulina.
|
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
|
EP3512880A1
(en)
|
2016-09-15 |
2019-07-24 |
Ablynx NV |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
JP7466308B2
(ja)
|
2016-09-20 |
2024-04-12 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法
|
|
EP3519438A1
(en)
|
2016-09-30 |
2019-08-07 |
VHsquared Limited |
Compositions
|
|
JP7222888B2
(ja)
|
2016-11-16 |
2023-02-15 |
アブリンクス エン．ヴェー． |
Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
|
|
CA3044729A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
KR20210087108A
(ko)
|
2016-11-23 |
2021-07-09 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
US12060654B2
(en)
|
2016-11-28 |
2024-08-13 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
|
MX2019006574A
(es)
|
2016-12-07 |
2019-08-21 |
Ablynx Nv |
Aglutinantes de albumina de suero mejorados.
|
|
WO2018111099A1
(en)
|
2016-12-12 |
2018-06-21 |
Stichting Vumc |
Biomarkers and treatments for cerebral amyloid angiopathy (caa)
|
|
IL312292A
(en)
|
2017-01-17 |
2024-06-01 |
Ablynx Nv |
Improved serum albumin binders
|
|
CA3050574A1
(en)
|
2017-01-17 |
2018-07-26 |
Ablynx Nv |
Improved serum albumin binders
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
CA3054623A1
(en)
|
2017-02-28 |
2018-09-07 |
Vib Vzw |
Means and methods for oral protein delivery
|
|
CN110546506B
(zh)
|
2017-03-31 |
2023-04-04 |
埃博灵克斯股份有限公司 |
改进的免疫原性测定法
|
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
|
CA3062238A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
|
WO2018209304A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
IL300964A
(en)
|
2017-05-12 |
2023-04-01 |
Harpoon Therapeutics Inc |
mesothelin binding proteins
|
|
HUE067691T2
(hu)
|
2017-05-31 |
2024-11-28 |
Boehringer Ingelheim Int |
A tumorsejtekben a Wnt jelátvitelt antagonizáló polipeptidek
|
|
JP7249961B2
(ja)
|
2017-06-02 |
2023-03-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
|
|
EP3630818A1
(en)
|
2017-06-02 |
2020-04-08 |
Ablynx NV |
Aggrecan binding immunoglobulins
|
|
ES3002733T3
(en)
|
2017-06-02 |
2025-03-07 |
Merck Patent Gmbh |
Adamts binding immunoglobulins
|
|
WO2018220235A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
|
US11820822B2
(en)
|
2017-06-06 |
2023-11-21 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
|
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
|
US11155607B2
(en)
|
2017-07-19 |
2021-10-26 |
Vib Vzw |
Serum albumin binding agents
|
|
EP3683234A1
(en)
|
2017-09-13 |
2020-07-22 |
Jiangsu Hengrui Medicine Co., Ltd. |
Il-6r antibody and antigen binding fragment thereof and medical use
|
|
CN107492601A
(zh)
*
|
2017-09-30 |
2017-12-19 |
京东方科技集团股份有限公司 |
一种显示器件及其封装方法、显示装置
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
PE20201183A1
(es)
|
2017-10-13 |
2020-11-03 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso
|
|
EP3698808B1
(en)
|
2017-10-20 |
2025-01-01 |
Hyogo College Of Medicine |
Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
|
JP7760115B2
(ja)
|
2017-10-31 |
2025-10-27 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
新規抗原結合性キメラタンパク質とその方法及び使用
|
|
MA50893A
(fr)
|
2017-11-15 |
2020-09-23 |
Novo Nordisk As |
Liants de facteur x renforçant l'activation fx
|
|
JP7482630B2
(ja)
|
2017-11-28 |
2024-05-14 |
中外製薬株式会社 |
抗原結合ドメインおよび運搬部分を含むポリペプチド
|
|
SG11202004627WA
(en)
|
2017-11-28 |
2020-06-29 |
Chugai Pharmaceutical Co Ltd |
Ligand-binding molecule having adjustable ligand-binding activity
|
|
CN120290578A
(zh)
|
2018-01-26 |
2025-07-11 |
瑞泽恩制药公司 |
抗tmprss2抗体和抗原结合片段
|
|
CN111670202A
(zh)
|
2018-02-06 |
2020-09-15 |
埃博灵克斯股份有限公司 |
以免疫球蛋白单可变结构域治疗ttp初次发作的方法
|
|
WO2019155041A1
(en)
|
2018-02-12 |
2019-08-15 |
Vib Vzw |
Gβγ COMPLEX ANTIBODIES AND USES THEREOF
|
|
CN111655296A
(zh)
|
2018-02-26 |
2020-09-11 |
埃博灵克斯股份有限公司 |
编码肽接头的经改良核苷酸序列
|
|
CA3090305A1
(en)
|
2018-02-28 |
2019-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
EP3758742A1
(en)
|
2018-03-01 |
2021-01-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
|
JOP20200258A1
(ar)
|
2018-04-09 |
2020-10-11 |
Amgen Inc |
البروتينات الاندماجية لعامل تمايز النمو 15
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
CA3114038A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
|
TWI860325B
(zh)
|
2019-01-31 |
2024-11-01 |
法商賽諾菲生物技術公司 |
用於治療幼年原發性關節炎之組成物及方法
|
|
ES2984072T3
(es)
|
2019-03-08 |
2024-10-28 |
Linxis B V |
Moléculas de unión internalizantes que actúan sobre receptores implicados en la proliferación celular o en ladiferenciación celular
|
|
BR112021021077A2
(pt)
|
2019-04-24 |
2021-12-14 |
E Zilberstein Moshe |
Métodos de diagnóstico e tratamento de artrite reumatoide
|
|
KR20220016077A
(ko)
|
2019-04-29 |
2022-02-08 |
콘포 테라퓨틱스 엔.브이. |
Gpcr에 결합하는 화합물 및 리간드를 스크리닝하는 키메라 단백질 및 방법
|
|
EP3962599A1
(en)
|
2019-04-30 |
2022-03-09 |
Vib Vzw |
Cystic fibrosis transmembrane conductance regulator stabilizing agents
|
|
WO2020223121A1
(en)
|
2019-04-30 |
2020-11-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
|
CN114245806A
(zh)
|
2019-05-14 |
2022-03-25 |
哈普恩治疗公司 |
EpCAM结合蛋白及使用方法
|
|
WO2020239945A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cancer treatment by targeting plexins in the immune compartment
|
|
WO2020239934A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
|
MX2021014892A
(es)
|
2019-06-04 |
2022-06-27 |
Sanofi Biotechnology |
Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.
|
|
KR20220064953A
(ko)
|
2019-06-21 |
2022-05-19 |
소리소 파마슈티컬스 인크. |
폴리펩티드
|
|
EP3986571A1
(en)
|
2019-06-21 |
2022-04-27 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
CN115066435B
(zh)
|
2019-09-20 |
2025-05-02 |
英韦克泰斯股份公司 |
针对lilrb2的单域抗体
|
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
|
EP4048703A1
(en)
|
2019-10-21 |
2022-08-31 |
Vib Vzw |
Nanodisc-specific antigen-binding chimeric proteins
|
|
WO2021095031A2
(en)
|
2019-11-11 |
2021-05-20 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Insect control nanobodies and uses thereof
|
|
WO2021105438A1
(en)
|
2019-11-27 |
2021-06-03 |
Vib Vzw |
Positive allosteric modulators of the calcium-sensing receptor
|
|
WO2021113736A1
(en)
|
2019-12-05 |
2021-06-10 |
Massachusetts Institute Of Technology |
Single-domain antibody to chloramphenicol
|
|
CN114981300B
(zh)
|
2019-12-06 |
2025-10-31 |
艾伯霖克斯公司 |
包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
|
|
BR112022010231A2
(pt)
|
2019-12-06 |
2022-09-06 |
Ablynx Nv |
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l
|
|
TWI861302B
(zh)
|
2019-12-09 |
2024-11-11 |
比利時商艾伯霖克斯公司 |
包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
WO2021123360A1
(en)
|
2019-12-20 |
2021-06-24 |
Vib Vzw |
Nanobody exchange chromatography
|
|
WO2021140205A1
(en)
|
2020-01-10 |
2021-07-15 |
Confo Therapeutics N.V. |
Methods for generating antibodies and antibody fragments and libraries comprising same
|
|
US20230075965A1
(en)
|
2020-01-24 |
2023-03-09 |
Constantine S. Mitsiades |
Uses of biomarkers for improving immunotherapy
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
WO2021163076A1
(en)
|
2020-02-10 |
2021-08-19 |
Regeneron Pharmaceuticals, Inc. |
ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
|
|
AU2021224851A1
(en)
|
2020-02-21 |
2022-09-15 |
Harpoon Therapeutics, Inc. |
FLT3 binding proteins and methods of use
|
|
EP4110794A1
(en)
|
2020-02-25 |
2023-01-04 |
Vib Vzw |
Leucine-rich repeat kinase 2 allosteric modulators
|
|
JP2023519967A
(ja)
|
2020-03-30 |
2023-05-15 |
アブリンクス・エヌ・フェー |
多価免疫グロブリン単一可変ドメインの製造及び精製のための方法
|
|
MX2021004130A
(es)
|
2020-04-02 |
2021-06-15 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno.
|
|
CN113527488A
(zh)
|
2020-04-22 |
2021-10-22 |
迈威(上海)生物科技股份有限公司 |
一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
|
|
KR20230017815A
(ko)
|
2020-05-26 |
2023-02-06 |
리제너론 파아마슈티컬스, 인크. |
항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
EP4214235A1
(en)
|
2020-09-16 |
2023-07-26 |
LinXis B.V. |
Internalizing binding molecules
|
|
CA3196737A1
(en)
|
2020-09-24 |
2022-03-31 |
Massimiliano Mazzone |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
|
BR112023005273A2
(pt)
|
2020-09-25 |
2023-04-25 |
Ablynx Nv |
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l
|
|
JP2023548046A
(ja)
|
2020-10-23 |
2023-11-15 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃ５抗体を使用する、補体障害を有する患者の処置方法
|
|
JP2024508207A
(ja)
|
2020-12-02 |
2024-02-26 |
ブイアイビー ブイゼットダブリュ |
がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
US11946055B2
(en)
*
|
2020-12-10 |
2024-04-02 |
The Regents Of The University Of California |
Protein engineering via error-prone orthogonal replication and yeast surface display
|
|
TW202241948A
(zh)
|
2020-12-18 |
2022-11-01 |
比利時商艾伯霖克斯公司 |
基於TCR α/β反應性的T細胞募集多肽
|
|
AU2021399955A1
(en)
|
2020-12-18 |
2023-08-03 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
|
|
US11897951B2
(en)
|
2020-12-18 |
2024-02-13 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
|
|
GB202020502D0
(en)
|
2020-12-23 |
2021-02-03 |
Vib Vzw |
Antibody composistion for treatment of corona virus infection
|
|
WO2022136649A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Non-blocking human ccr8 binders
|
|
EP4267617A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Human ccr8 binders
|
|
EP4267621A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
JP2024506020A
(ja)
|
2021-02-05 |
2024-02-08 |
ブイアイビー ブイゼットダブリュ |
サルベコウイルス結合剤
|
|
AU2022218771A1
(en)
|
2021-02-11 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancers using sting agonists
|
|
EP4294407A1
(en)
|
2021-02-17 |
2023-12-27 |
Vib Vzw |
Inhibition of slc4a4 in the treatment of cancer
|
|
CA3211270A1
(en)
|
2021-02-19 |
2022-08-25 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders
|
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
|
US12454572B2
(en)
|
2021-03-02 |
2025-10-28 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating anemia in myelodysplastic syndromes
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
EP4319800A1
(en)
|
2021-04-07 |
2024-02-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for the treatment of cancer
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
US20240280561A1
(en)
|
2021-06-08 |
2024-08-22 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
|
WO2022268993A1
(en)
|
2021-06-23 |
2022-12-29 |
Vib Vzw |
Means and methods for selection of specific binders
|
|
IL310012A
(en)
|
2021-07-14 |
2024-03-01 |
Regeneron Pharma |
Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
|
|
JP2024530455A
(ja)
|
2021-07-30 |
2024-08-21 |
ブイアイビー ブイゼットダブリュ |
標的化タンパク質の分解のためのカチオン非依存性マンノース６リン酸受容体結合体
|
|
US20240409638A1
(en)
|
2021-10-07 |
2024-12-12 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
|
CN114085287B
(zh)
*
|
2021-11-12 |
2022-10-25 |
中国农业科学院北京畜牧兽医研究所 |
犬细小病毒纳米抗体cpv-vhh-f5及其应用
|
|
WO2023091704A1
(en)
|
2021-11-18 |
2023-05-25 |
Circularis Biotechnologies, Inc. |
Compositions and methods for production of circular nucleic acid molecules
|
|
EP4437547A1
(en)
|
2021-11-22 |
2024-10-02 |
Ablynx N.V. |
Obtaining sequence information for target multivalent immunoglobulin single variable domains
|
|
US20250381241A1
(en)
|
2021-11-29 |
2025-12-18 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
|
EP4448574A1
(en)
|
2021-12-17 |
2024-10-23 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
|
|
WO2023135198A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
Human ntcp binders for therapeutic use and liver-specific targeted delivery
|
|
EP4476250A1
(en)
|
2022-02-07 |
2024-12-18 |
Vib Vzw |
Engineered stabilizing aglycosylated fc-regions
|
|
EP4477665A4
(en)
|
2022-02-10 |
2025-08-20 |
Affyxell Therapeutics Co Ltd |
STEFIN A PROTEIN VARIANTS THAT SPECIFICALLY BIND TO CD40L AND THEIR USES
|
|
WO2023155902A1
(en)
|
2022-02-18 |
2023-08-24 |
Chongqing Mingdao Haoyue Biotechnology Co., Ltd. |
Intranasal formulations and anti-sars-cov-2-spike protein antibodies
|
|
US20250235534A1
(en)
|
2022-04-13 |
2025-07-24 |
Vib Vzw |
An LTBR Agonist In Combination Therapy Against Cancer
|
|
WO2023215498A2
(en)
*
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
IL316708A
(en)
|
2022-05-18 |
2024-12-01 |
Vib Vzw |
Cerbevirus S2 spike subunit binding
|
|
IL317461A
(en)
|
2022-06-08 |
2025-02-01 |
Tidal Therapeutics Inc |
Ionized Cationic Lipids and Lipid Nanoparticles and Methods of Synthesis and Use thereof
|
|
JP2025530888A
(ja)
|
2022-06-14 |
2025-09-18 |
アブリンクス エン．ヴェー． |
Ｔ細胞レセプターを標的とするイムノグロブリン単一可変ドメイン
|
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
|
JP2025525566A
(ja)
|
2022-07-18 |
2025-08-05 |
アブリンクス エン．ヴェー． |
Ｃｘ３ｃｒ１結合化合物、その使用及び関連する方法
|
|
TW202423965A
(zh)
|
2022-07-27 |
2024-06-16 |
比利時商艾伯霖克斯公司 |
與新生兒fc受體的特定表位結合之多肽
|
|
CN116162160B
(zh)
*
|
2022-08-05 |
2025-07-29 |
南京融捷康生物科技有限公司 |
一种抗il-6的单域抗体及其用途
|
|
AU2023330110A1
(en)
|
2022-08-22 |
2025-03-06 |
Abdera Therapeutics Inc. |
Dll3 binding molecules and uses thereof
|
|
EP4594348A1
(en)
|
2022-09-27 |
2025-08-06 |
Vib Vzw |
Antivirals against human parainfluenza virus
|
|
TW202430561A
(zh)
|
2022-09-30 |
2024-08-01 |
法商賽諾菲公司 |
抗cd28抗體
|
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
IL320455A
(en)
|
2022-10-25 |
2025-06-01 |
Ablynx Nv |
Glyco-engineered polypeptide variants of FC with enhanced effector function
|
|
AU2023376684A1
(en)
|
2022-11-09 |
2025-06-19 |
Merck Patent Gmbh |
Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
EP4638502A2
(en)
|
2022-12-21 |
2025-10-29 |
Genzyme Corporation |
Anti-pd-1×4-1bb binding proteins
|
|
US20240415974A1
(en)
|
2022-12-23 |
2024-12-19 |
Ablynx N.V. |
Protein-based conjugation carriers
|
|
EP4648792A2
(en)
|
2023-01-09 |
2025-11-19 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2024156881A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
CD8b-BINDING POLYPEPTIDES
|
|
WO2024156888A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
Cd163-binding conjugates
|
|
CN121013866A
(zh)
|
2023-02-10 |
2025-11-25 |
阿穆尼克斯制药公司 |
靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
|
|
AR131869A1
(es)
|
2023-02-17 |
2025-05-07 |
Ablynx Nv |
POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
|
|
WO2024175787A1
(en)
|
2023-02-24 |
2024-08-29 |
Vrije Universiteit Brussel |
Anti-inflammatory pannexin 1 channel inhibitors
|
|
WO2024192065A1
(en)
|
2023-03-14 |
2024-09-19 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
AU2024240129A1
(en)
|
2023-03-17 |
2025-10-09 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
FR3147278A1
(fr)
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
|
WO2024200987A1
(en)
|
2023-03-31 |
2024-10-03 |
Avacta Life Sciences Limited |
Tnfr2 binding polypeptides and methods of use
|
|
AU2024243709A1
(en)
|
2023-04-03 |
2025-11-06 |
Katholieke Universiteit Leuven |
Blood-brain barrier crossing antibodies
|
|
CN121398855A
(zh)
|
2023-04-24 |
2026-01-23 |
默沙东有限责任公司 |
Trop2结合剂及其缀合物
|
|
CN121079319A
(zh)
|
2023-05-08 |
2025-12-05 |
赛诺菲 |
免疫球蛋白单可变结构域的糖基化
|
|
WO2024231348A1
(en)
|
2023-05-11 |
2024-11-14 |
Vib Vzw |
Slc4a4/nbce1 inhibitors
|
|
WO2024238790A1
(en)
|
2023-05-17 |
2024-11-21 |
Odyssey Therapeutics, Inc. |
Modified single-domain antibodies
|
|
WO2024251783A1
(en)
|
2023-06-05 |
2024-12-12 |
Sanofi |
Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
|
|
WO2024261235A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Chimeric proteins for modulating cytokine receptor activity
|
|
WO2024261338A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting pd-l1
|
|
WO2024261344A1
(en)
|
2023-06-23 |
2024-12-26 |
Vib Vzw |
Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
|
|
WO2025006846A2
(en)
|
2023-06-29 |
2025-01-02 |
Odyssey Therapeutics, Inc. |
Anti-trailr2 antigen-binding proteins and uses thereof
|
|
AR133188A1
(es)
|
2023-07-05 |
2025-09-03 |
Ablynx Nv |
ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
|
|
TW202521562A
(zh)
|
2023-08-11 |
2025-06-01 |
美商默沙東有限責任公司 |
單價介白素-12(IL-12) 異二聚體Fc蛋白
|
|
TW202525845A
(zh)
|
2023-08-23 |
2025-07-01 |
法商賽諾菲公司 |
基於ｃｔｌａ—４之溶體降解劑及其用途
|
|
TW202525843A
(zh)
|
2023-09-04 |
2025-07-01 |
法商賽諾菲公司 |
用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
|
|
TW202532432A
(zh)
|
2023-09-22 |
2025-08-16 |
比利時商艾伯霖克斯公司 |
二及多價白蛋白結合劑
|
|
TW202530265A
(zh)
|
2023-10-13 |
2025-08-01 |
美商奧迪希治療公司 |
抗cdh17抗原結合蛋白及其用途
|
|
WO2025088546A1
(en)
|
2023-10-25 |
2025-05-01 |
Ablynx N.V. |
Fc domain variants with enhanced fc receptor binding
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
WO2025099632A1
(en)
|
2023-11-08 |
2025-05-15 |
Sanofi |
Cd25 based lysosomal degrader and uses thereof
|
|
WO2025109176A1
(en)
|
2023-11-22 |
2025-05-30 |
Exevir Bio Bv |
Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
|
|
WO2025114555A1
(en)
|
2023-11-30 |
2025-06-05 |
Oncospear Aps |
Anti-cd163 antibodies with improved adcc capabilities
|
|
WO2025114529A1
(en)
|
2023-12-01 |
2025-06-05 |
Ablynx Nv |
Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
|
|
WO2025125577A1
(en)
|
2023-12-14 |
2025-06-19 |
Vib Vzw |
Antibodies against influenza b virus
|
|
WO2025133253A2
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based conjugation carriers for intranuclear delivery
|
|
WO2025133166A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based carriers for site-specific amine conjugation
|
|
WO2025133252A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting ceacam5
|
|
WO2025154058A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect hsp70 nanobodies and uses thereof
|
|
WO2025154056A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect cda nanobodies and uses thereof
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025181155A1
(en)
|
2024-02-26 |
2025-09-04 |
Vib Vzw |
Human beta-glucocerebrosidase binders and uses thereof
|
|
GB202403780D0
(en)
|
2024-03-15 |
2024-05-01 |
Avacta Life Sciences Ltd |
Polypeptides and methods for detecting and quantifying small molecules
|
|
WO2025196308A1
(en)
|
2024-03-22 |
2025-09-25 |
Vib Vzw |
Means and methods for displaying fc-containing proteins on cells and selection thereof
|
|
WO2025207946A1
(en)
|
2024-03-28 |
2025-10-02 |
Genzyme Corporation |
Polypeptides binding to a specific epitope of the transferrin receptor 1
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025219231A1
(en)
|
2024-04-15 |
2025-10-23 |
Vib Vzw |
Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
|
|
WO2025229161A1
(en)
|
2024-05-01 |
2025-11-06 |
Commit Biologics Aps |
Engineered complement engaging polypeptides
|
|
WO2025238157A1
(en)
|
2024-05-15 |
2025-11-20 |
Katholieke Universiteit Leuven |
Multispecific binding agent suitable for use in cancer immune therapy
|
|
WO2025255558A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
|
|
WO2025255435A2
(en)
|
2024-06-07 |
2025-12-11 |
Odyssey Therapeutics, Inc. |
Antigen-binding proteins against serum albumin and uses thereof
|
|
WO2025257408A1
(en)
|
2024-06-14 |
2025-12-18 |
Sanofi |
Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
|
|
WO2025262150A2
(en)
|
2024-06-18 |
2025-12-26 |
Ablynx Nv |
Antibody-recruiting molecules
|
|
WO2026006809A1
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Multispecific molecules binding tnfr2 and cd25 and uses thereof
|
|
WO2026006708A2
(en)
|
2024-06-27 |
2026-01-02 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
WO2026008664A1
(en)
|
2024-07-01 |
2026-01-08 |
Vib Vzw |
Allosteric modulators of inhibitory immune receptor complexes
|
|
WO2026024863A2
(en)
|
2024-07-24 |
2026-01-29 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
|